Inactive C8A‑humanin analog is as stable as a potent S14G‑humanin analog

Arakawa,Tsutomu; Niikura,Takako; Kita,Yoshiko

doi:10.3892/mmr.2013.1797

Inactive C8A‑humanin analog is as stable as a potent S14G‑humanin analog

Authors:
- Tsutomu Arakawa
- Takako Niikura
- Yoshiko Kita
View Affiliations

Affiliations: Alliance Protein Laboratories Inc., San Diego, CA 92121‑4746, USA, Simon Fraser University, Burnaby, BC V5A 1S6, Canada, Department of Pharmacology, Keio University School of Medicine, Tokyo 160‑8582, Japan
Published online on: November 14, 2013 https://doi.org/10.3892/mmr.2013.1797
Pages: 375-379

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

We have previously shown that the structural stability of humanin (HN), a neuroprotective peptide ligand, is one of the attributes to the observed activity differences between HN analogs. It has been observed that the activity increased consecutively in the S7A‑HN analog, the parent HN and the S14G‑HN analog, consistent with the increased stability observed in that order. In the present study, the structure and stability of another inactive analog, C8A‑HN, was measured, which has been revealed to have no neuroprotective activity similar to that of the S7A‑HN analog and hence may have compromised stability. While all these analogs of HN demonstrated a similar disordered secondary structure in phosphate-buffered saline at 5˚C, as determined by circular dichroism spectroscopy, they revealed different structures at 37˚C. At 37˚C, less active HN and inactive S7A‑HN revealed a structure with a valley at ~217 nm, indicating a conversion from the disordered structure to a β‑sheet. Such a conversion was largely irreversible. By contrast, C8A‑HN and S14G‑HN demonstrated a similar structure at 37˚C and at 5˚C and remained largely disordered. The observed small structural changes of the C8A‑HN analog at 37˚C and its reversibility upon cooling do not support a hypothesis that the instability at 37˚C may have caused the reduced activity of this analog. Therefore an alternative explanation for its activity loss is required.

View Figures

View References

1	Fields K, Falla TJ, Rodan K and Bush L: Bioactive peptides: signaling the future. J Cosmet Dermatol. 8:8–13. 2009. View Article : Google Scholar : PubMed/NCBI
2	Aneiros A and Garateix A: Bioactive peptides from marine sources: pharmacological properties and isolation procedures. J Chromatogr B Analyt Technol Biomed Life Sci. 803:41–53. 2004.PubMed/NCBI
3	Mason JM: Design and development of peptides and peptide mimetics as antagonists for therapeutic intervention. Future Med Chem. 2:1813–1822. 2010. View Article : Google Scholar : PubMed/NCBI
4	Otvos L Jr: Synthesis of a multivalent, multiepitope vaccine construct. Methods Mol Biol. 494:263–273. 2008. View Article : Google Scholar : PubMed/NCBI
5	Hashimoto Y, Niikura T, Tajima H, et al: A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer’s disease genes and Abeta. Proc Natl Acad Sci USA. 98:6336–6341. 2001.PubMed/NCBI
6	Yamagishi Y, Hashimoto Y, Niikura T and Nishimoto I: Identification of essential amino acids in Humanin, a neuroprotective factor against Alzheimer’s disease-relevant insults. Peptides. 24:585–595. 2003.PubMed/NCBI
7	Hashimoto Y, Kurita M and Matsuoka M: Identification of soluble WSX-1 not as a dominant-negative but as an alternative functional subunit of a receptor for an anti-Alzheimer’s disease rescue factor Humanin. Biochem Biophys Res Commun. 389:95–99. 2009.
8	Hashimoto Y, Niikura T, Ito Y, et al: Detailed characterization of neuroprotection by a rescue factor humanin against various Alzheimer’s disease-relevant insults. J Neurosci. 21:9235–9245. 2001.PubMed/NCBI
9	Ikonen M, Liu B, Hashimoto Y, et al: Interaction between the Alzheimer’s survival peptide humanin and insulin-like growth factor-binding protein 3 regulates cell survival and apoptosis. Proc Natl Acad Sci USA. 100:13042–13047. 2003.
10	Terashita K, Hashimoto Y, Niikura T, et al: Two serine residues distinctly regulate the rescue function of Humanin, an inhibiting factor of Alzheimer’s disease-related neurotoxicity: functional potentiation by isomerization and dimerization. J Neurochem. 85:1521–1538. 2003.PubMed/NCBI
11	Armas A, Sonois V, Mothes E, Mazarguil H and Faller P: Zinc(II) binds to the neuroprotective peptide humanin. J Inorg Biochem. 100:1672–1678. 2006. View Article : Google Scholar : PubMed/NCBI
12	Arakawa T, Niikura T and Kita Y: The biological activity of Humanin analogs correlates with structure stabilities in solution. Int J Biol Macromol. 49:93–97. 2011. View Article : Google Scholar : PubMed/NCBI
13	Arisaka F, Arakawa T, Niikura T and Kita Y: Active form of neuroprotective Humanin, HN, and inactive analog, S7A-HN, are monomeric and disordered in aqueous phosphate solution at pH 6.0; No correlation of solution structure with activity. Protein Pept Lett. 16:132–137. 2009. View Article : Google Scholar
14	Thies MJ, Talamo F, Mayer M, et al: Folding and oxidation of the antibody domain C(H)3. J Mol Biol. 319:1267–1277. 2002. View Article : Google Scholar : PubMed/NCBI
15	Arakawa T, Niikura T, Tajima H and Kita Y: The secondary structure analysis of a potent Ser14Gly analog of antiAlzheimer peptide, Humanin, by circular dichroism. J Pept Sci. 12:639–642. 2006. View Article : Google Scholar : PubMed/NCBI
16	Arakawa T, Kita Y and Niikura T: A rescue factor for Alzheimer’s diseases: discovery, activity, structure, and mechanism. Curr Med Chem. 15:2086–2098. 2008.
17	Pistolesi S, Rossini L, Ferro E, Basosi R, Trabalzini L and Pogni R: Humanin structural versatility and interaction with model cerebral cortex membranes. Biochemistry. 48:5026–5033. 2009. View Article : Google Scholar : PubMed/NCBI
18	Maurer-Stroh S, Debulpaep M, Kuemmerer N, et al: Exploring the sequence determinants of amyloid structure using position-specific scoring matrices. Nature Methods. 7:237–242. 2010. View Article : Google Scholar : PubMed/NCBI
19	Nozaki Y and Tanford C: The solubility of amino acids and two glycine peptides in aqueous ethanol and dioxane solutions. Establishment of a hydrophobicity scale. J Biol Chem. 246:2211–2217. 1971.PubMed/NCBI
20	Richardson JS and Richardson DC: Principles and patterns of protein conformation. Prediction of Protein Structure and the Principles of Protein Conformation. Fasman G: Plenum Press; New York: pp. 43–75. 1989
21	Kyte J and Doolittle RF: A simple method for displaying the hydropathic character of a protein. J Mol Biol. 157:105–132. 1982. View Article : Google Scholar : PubMed/NCBI
22	Zhou X, Liu J, Li B, Pillai S, Lin D, Liu J and Zhang Y: Assembly of glucagon (proto)fibrils by longitudinal addition of oligomers. Nanoscale. 3:3049–3051. 2011. View Article : Google Scholar : PubMed/NCBI
23	Arvinte T, Cudd A and Drake AF: The structure and mechanism of formation of human calcitonin fibrils. J Biol Chem. 268:6415–6422. 1993.PubMed/NCBI
24	Steckmann T, Awan Z, Gerstman BS and Chapagain PP: Kinetics of peptide secondary structure conversion during amyloid β-protein fibrillogenesis. J Theor Biol. 301:95–102. 2012.
25	Kodali R, Williams AD, Chemuru S and Wetzel R: Abeta(1–40) forms five distinct amyloid structures whose beta-sheet contents and fibril stabilities are correlated. J Mol Biol. 401:503–517. 2010.
26	Macchi F, Hoffmann SV, Carlsen M, et al: Mechanical stress affects glucagon fibrillation kinetics and fibril structure. Langmuir. 27:12539–12549. 2011. View Article : Google Scholar : PubMed/NCBI